|
Market Closed -
Nasdaq
16:00:00 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 20.56 USD | +1.58% |
|
-3.38% | -10.65% |
| 09-20 | Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to S&P Global BMI Index | CI |
| 08-10 | Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Damora Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 76.54 | 29.42 | 19.52 | 6.124 | 36.75 | 1,250 | - | - |
| Change | - | -61.57% | -33.64% | -68.63% | 500.17% | 3,299.67% | - | - |
| Enterprise Value (EV) 1 | 13.98 | -3.368 | -13.63 | 6.124 | -220.9 | 788 | 897.7 | 765.3 |
| Change | - | -124.09% | -304.71% | 144.93% | -3,706.63% | 456.76% | 13.93% | -14.75% |
| P/E | -1.48x | -0.47x | -0.5x | -0.25x | -5.78x | -10.3x | -9.89x | -8.01x |
| PBR | 0.65x | 0.47x | - | - | 5.77x | 2.5x | 3.78x | 2.99x |
| PEG | - | -0x | 0x | 0x | 0.1x | 0.2x | -2.56x | -0.3x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | -0.27x | 0.06x | - | - | 1.05x | -5.53x | -6.03x | -4.92x |
| EV / EBIT | -0.27x | 0.06x | 0.34x | -0.28x | 1.05x | -5.62x | -5.35x | -3.6x |
| EV / FCF | -0.27x | 0.08x | - | - | - | -6.2x | -5.48x | -3.68x |
| FCF Yield | -376% | 1,281% | - | - | - | -16.1% | -18.3% | -27.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -51.25 | -60.75 | -36 | -18.53 | -3.98 | -2.002 | -2.079 | -2.566 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | -51.79 | -60.72 | - | - | -210.8 | -142.6 | -149 | -155.6 |
| EBIT 1 | -52.23 | -61.21 | -39.9 | -22.26 | -210.9 | -140.3 | -167.7 | -212.5 |
| Net income 1 | -51.75 | -61.62 | -38.35 | -21.44 | -209.8 | -125.6 | -151.3 | -198 |
| Net Debt 1 | -62.56 | -32.79 | -33.15 | - | -257.6 | -461.6 | -351.8 | -484.2 |
| Reference price 2 | 75.75 | 28.75 | 18.00 | 4.65 | 23.01 | 20.56 | 20.56 | 20.56 |
| Nbr of stocks (in thousands) | 1,010 | 1,023 | 1,085 | 1,317 | 1,597 | 61,736 | - | - |
| Announcement Date | 2/17/22 | 3/9/23 | 3/8/24 | 3/19/25 | 3/19/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -10.11x | - | -5.53x | -.--% | 1.25B | |
| 21.73x | 7.76x | 15.59x | 1.37% | 74.68B | |
| 30.5x | 8.78x | 27.34x | 0.04% | 58.7B | |
| 33.66x | 6.05x | 18.11x | 0.96% | 48.36B | |
| -20.81x | 215.3x | -22.29x | -.--% | 43.05B | |
| 33.24x | 3.23x | 13.97x | -.--% | 42.48B | |
| 48.26x | 5.5x | 30.21x | -.--% | 41.39B | |
| 27.77x | 7.89x | 20.51x | 0.41% | 31.29B | |
| -14.93x | 5.54x | -6.96x | -.--% | 23.93B | |
| -61.76x | 11.97x | -60.92x | -.--% | 22.22B | |
| Average | 8.76x | 30.22x | 3.00x | 0.28% | 38.74B | |
| Weighted average by Cap. | 17.25x | 30.22x | 9.41x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DMRA Stock
- Valuation Damora Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
